Siemens Healthineers: A Stock at War With Its Own Analyst Targets

Siemens Healthineers trades near a 52-week low with 50% analyst upside, as a spin-off plan advances amid tariff risks and a crucial Q2 report on May 7.

The numbers tell a story of two competing realities. On one side, the average analyst price target for Siemens Healthineers sits at roughly 53.50 euros, implying more than 50 percent upside from current levels. On the other, the stock has shed nearly a quarter of its value over the past twelve months and now trades at 35.75 euros — barely above its 52-week low and roughly 18 percent below its 200-day moving average.

That gap between market pessimism and Wall Street conviction has rarely been wider. And with the next major catalyst just days away, something will have to give.

The Spin-Off Roadmap Takes Shape

Siemens is pressing ahead with plans to sever formal ties with its medical technology subsidiary, a move that could fundamentally reshape the company's strategic autonomy. Under the current blueprint, shareholders at the parent company's annual general meeting in February 2027 will vote on transferring 30 percent of Healthineers shares directly to Siemens investors under Germany's Umwandlungsgesetz (transformation law). That would cut Siemens' stake from roughly 67 percent today to about 37 percent, surrendering the majority holding.

The longer-term ambition is to reduce the position further, to below 20 percent. A critical piece of the puzzle fell into place recently when Moody's assigned an "A3" investment-grade rating to Healthineers, paving the way for independent refinancing without the backing of the Munich-based parent. What remains unresolved is the tax treatment: Siemens expects the in-specie distribution of new shares to be tax-free for holders, but final regulatory confirmation has yet to arrive.

Operational Headwinds Pile Up

While the corporate restructuring story offers a narrative of liberation, the day-to-day business is telling a different tale. Revenue in the first quarter edged higher, but adjusted earnings per share slid three percent. The diagnostics division, in particular, is struggling — shrinking noticeably as persistent difficulties in the Chinese market weigh on performance.

The headwinds are only intensifying. Management has flagged that US tariffs could cost the company up to 500 million euros this year, while a strengthening euro is expected to shave another 200 to 250 million euros off operating profit. Those pressures have left deep marks on the chart: the stock has fallen roughly 20 percent since the start of the year, and its relative strength index of 25.5 signals deeply oversold conditions — a level that catches the eye of contrarian investors but does not in itself constitute a buy signal.

The Q2 Reckoning

All eyes now turn to May 7, when Healthineers reports second-quarter results. Analysts expect revenue to be essentially flat at just under six billion euros, with earnings per share declining to 0.51 euros. Management has already warned that top-line growth in the period will fall short of its targeted range.

The focus on reporting day will be squarely on margin trends in the imaging business and any signs of stabilization in the Chinese diagnostics market. Without them, the stock could quickly test its recent lows. Conversely, positive surprises — particularly around the integration of artificial intelligence into clinical workflows — would provide the first real test of whether the floor around 35 euros can hold.

The divergence between analyst optimism and market reality is striking. RBC Capital Markets reaffirmed a 55-euro target in mid-April, while Jefferies and JPMorgan sit at 60 euros and 61.30 euros respectively, underpinned by expectations of annual earnings growth of roughly 11 to 12 percent. Whether those forecasts survive contact with the second-quarter numbers will become clear soon enough.